CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Bortezomib

硼替佐米 杂质对照品Bortezomib Impurities

53 个杂质条目53 impurity entries

本页汇总 硼替佐米 的 53 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 53 impurity reference standards of Bortezomib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 硼替佐米(Bortezomib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesPhysicochemical stability of bortezomib solutions for subcutaneous administration
    Scientific reports · 2024 · Gómez Á et al.  ·  PMID 38637597  ·  DOI
  2. 分析方法Analytical MethodsSeparation, identification and characterization of stress degradation products of bortezomib using HPLC and LC-MS
    European journal of mass spectrometry (Chichester, England) · 2021 · Purushotham Reddy C et al.  ·  PMID 33827302  ·  DOI
  3. 分析方法Analytical MethodsDetermination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities
    Journal of chromatographic science · 2017 · Kamalzadeh Z et al.  ·  PMID 28369337  ·  DOI
  4. 分析方法Analytical MethodsImproved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation
    Journal of proteome research · 2021 · Pino LK et al.  ·  PMID 33764077  ·  DOI
  5. 分析方法Analytical MethodsSimultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications
    Nanomedicine (London, England) · 2024 · Yadav PK et al.  ·  PMID 39115873  ·  DOI

硼替佐米 —— 原料药与杂质对照品Bortezomib — drug substance & impurities

共 54 个条目(含原料药本体)54 items incl. the drug substance
Bortezomib structure
原料药 APIAPIPeptide
硼替佐米Bortezomib
Bortezomib
Dipeptide boronic acid: pyrazine-2-carbonyl-Phe-boroLeu (peptidomimetic)
CAS No.179324-69-7
Chemical FormulaC19H25BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 1 structure
1
硼替佐米杂质1Bortezomib Impurity 1
Bortezomib Impurity 1
CAS No.289472-78-2
Chemical FormulaC19H24N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 2 structure
2
硼替佐米杂质2Bortezomib Impurity 2
Bortezomib Impurity 2
CAS No.289472-81-7
Chemical FormulaC19H24N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 3 structure
3
硼替佐米杂质3Bortezomib Impurity 3
Bortezomib Impurity 3
CAS No.289472-80-6
Chemical FormulaC14H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 4 structure
4
硼替佐米杂质4Bortezomib Impurity 4
Bortezomib Impurity 4
CAS No.886979-78-8
Chemical FormulaC19H24N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 5 structure
5
硼替佐米杂质5Bortezomib Impurity 5
Bortezomib Impurity 5
CAS No.886979-81-3
Chemical FormulaC19H24N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 6 structure
6
硼替佐米杂质6Bortezomib Impurity 6
Bortezomib Impurity 6
CAS No.114457-94-2
Chemical FormulaC14H13N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 7 structure
7
硼替佐米杂质7Bortezomib Impurity 7
Bortezomib Impurity 7
CAS No.1132709-15-9
Chemical FormulaC19H25BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 8 structure
8
硼替佐米杂质8Bortezomib Impurity 8
Bortezomib Impurity 8
CAS No.1132709-16-0
Chemical FormulaC19H25BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 9 structure
9
硼替佐米杂质9Bortezomib Impurity 9
Bortezomib Impurity 9
CAS No.1132709-14-8
Chemical FormulaC19H25BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 11 structure
11
硼替佐米杂质11Bortezomib Impurity 11
Bortezomib Impurity 11
CAS No.205393-22-2
Chemical FormulaC29H39BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 12 structure
12
硼替佐米杂质12Bortezomib Impurity 12
Bortezomib Impurity 12
CAS No.73058-37-4
Chemical FormulaC15H15N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 13 structure
13
硼替佐米杂质13Bortezomib Impurity 13
Bortezomib Impurity 13
CAS No.1608986-16-8
Chemical FormulaC14H13N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 15 structure
15
硼替佐米杂质15Bortezomib Impurity 15
Bortezomib Impurity 15
CAS No.275374-67-9
Chemical FormulaC24H31NO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 16 structure
16
硼替佐米杂质16Bortezomib Impurity 16
Bortezomib Impurity 16
CAS No.862895-00-9
Chemical FormulaC19H22N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 17 structure
17
硼替佐米杂质17Bortezomib Impurity 17
Bortezomib Impurity 17
CAS No.2379402-85-2
Chemical FormulaC19H22N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 22 structure
22
硼替佐米杂质22Bortezomib Impurity 22
Bortezomib Impurity 22
CAS No.84110-34-9
Chemical FormulaC14H25BO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 23 structure
23
硼替佐米杂质23Bortezomib Impurity 23
Bortezomib Impurity 23
CAS No.85167-14-2
Chemical FormulaC15H26BClO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 24 structure
24
硼替佐米杂质24Bortezomib Impurity 24
Bortezomib Impurity 24
CAS No.514820-48-5
Chemical FormulaC21H44BNO2Si2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 25 Monomer structure
25
硼替佐米杂质25单体Bortezomib Impurity 25 Monomer
Bortezomib Impurity 25 Monomer
CAS No.477254-68-5
Chemical FormulaC15H28BNO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 25 structure
25
硼替佐米杂质25Bortezomib Impurity 25
Bortezomib Impurity 25
CAS No.945606-99-5
Chemical FormulaC15H29BClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 26 structure
26
硼替佐米杂质26Bortezomib Impurity 26
Bortezomib Impurity 26
CAS No.18680-27-8
Chemical FormulaC10H18O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 27 structure
27
硼替佐米杂质27Bortezomib Impurity 27
Bortezomib Impurity 27
CAS No.1446194-56-4
Chemical FormulaC19H24N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 28 structure
28
硼替佐米杂质28Bortezomib Impurity 28
Bortezomib Impurity 28
CAS No.862894-96-0
Chemical FormulaC19H22N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 29 Hydrochloride structure
29
硼替佐米杂质29 盐酸盐Bortezomib Impurity 29 Hydrochloride
Bortezomib Impurity 29 Hydrochloride
CAS No.1158974-93-6
Chemical FormulaC5H14BNO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 29 structure
29
硼替佐米杂质29Bortezomib Impurity 29
Bortezomib Impurity 29
CAS No.389799-97-7
Chemical FormulaC5H14BNO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 30 structure
30
硼替佐米杂质30Bortezomib Impurity 30
Bortezomib Impurity 30
CAS No.1194235-41-0
Chemical FormulaC28H34BN5O5
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 38 structure
38
硼替佐米杂质38Bortezomib Impurity 38
Bortezomib Impurity 38
CAS No.390800-88-1
Chemical FormulaC57H69B3N12O9
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 40 structure
40
硼替佐米杂质40Bortezomib Impurity 40
Bortezomib Impurity 40
CAS No.948294-96-0
Chemical FormulaC14H23BN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 41 structure
41
硼替佐米杂质41Bortezomib Impurity 41
Bortezomib Impurity 41
CAS No.2493017-06-2
Chemical FormulaC11H25BClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 53 structure
53
硼替佐米杂质53Bortezomib Impurity 53
Bortezomib Impurity 53
CAS No.18942-49-9
Chemical FormulaC14H19NO4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 54 structure
54
硼替佐米杂质54Bortezomib Impurity 54
Bortezomib Impurity 54
CAS No.13734-34-4
Chemical FormulaC14H19NO4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 56 structure
56
硼替佐米杂质56Bortezomib Impurity 56
Bortezomib Impurity 56
CAS No.2276538-67-9
Chemical FormulaC19H22N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 57 structure
57
硼替佐米杂质57Bortezomib Impurity 57
Bortezomib Impurity 57
CAS No.119771-23-2
Chemical FormulaC14H20BNO6
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 58 structure
58
硼替佐米杂质58Bortezomib Impurity 58
Bortezomib Impurity 58
CAS No.111771-57-4
Chemical FormulaC14H20BNO6
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 60 structure
60
硼替佐米杂质60Bortezomib Impurity 60
Bortezomib Impurity 60
CAS No.1194235-14-7
Chemical FormulaC23H22N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 66 structure
66
硼替佐米杂质66Bortezomib Impurity 66
Bortezomib Impurity 66
CAS No.205393-21-1
Chemical FormulaC24H37BN2O3·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 68 structure
68
硼替佐米杂质68Bortezomib Impurity 68
Bortezomib Impurity 68
CAS No.1194235-43-2
Chemical FormulaC28H34BN5O6
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 70 structure
70
硼替佐米杂质70Bortezomib Impurity 70
Bortezomib Impurity 70
CAS No.21803-49-6
Chemical FormulaC10H18O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 75 structure
75
硼替佐米杂质75Bortezomib Impurity 75
Bortezomib Impurity 75
CAS No.2577-40-4
Chemical FormulaC18H20N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 77 structure
77
硼替佐米杂质77Bortezomib Impurity 77
Bortezomib Impurity 77
CAS No.94242-85-0
Chemical FormulaC7H15BO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 78 structure
78
硼替佐米杂质78Bortezomib Impurity 78
Bortezomib Impurity 78
CAS No.1375004-39-9
Chemical FormulaC29H39BN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 80 structure
80
硼替佐米杂质80Bortezomib Impurity 80
Bortezomib Impurity 80
CAS No.19847-10-0
Chemical FormulaC5H3ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 81 structure
81
硼替佐米杂质81Bortezomib Impurity 81
Bortezomib Impurity 81
CAS No.1187479-72-6
Chemical FormulaC29H45BN2O5
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 82 structure
82
硼替佐米杂质82Bortezomib Impurity 82
Bortezomib Impurity 82
CAS No.2363753-29-9
Chemical FormulaC15H28BNO2·C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 84 structure
84
硼替佐米杂质84Bortezomib Impurity 84
Bortezomib Impurity 84
CAS No.2413961-74-5
Chemical FormulaC34H44BN5O5
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 87 structure
87
硼替佐米杂质87Bortezomib Impurity 87
Bortezomib Impurity 87
CAS No.105869-43-0
Chemical FormulaC8H17BO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 88 structure
88
硼替佐米杂质88Bortezomib Impurity 88
Bortezomib Impurity 88
CAS No.139442-44-7
Chemical FormulaC12H9N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 89 structure
89
硼替佐米杂质89Bortezomib Impurity 89
Bortezomib Impurity 89
CAS No.1185915-80-3
Chemical FormulaC15H18BNO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 90 structure
90
硼替佐米杂质90Bortezomib Impurity 90
Bortezomib Impurity 90
CAS No.34420-17-2
Chemical FormulaC8H11BO2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 91 structure
91
硼替佐米杂质91Bortezomib Impurity 91
Bortezomib Impurity 91
CAS No.2185388-96-7
Chemical FormulaC14H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 92 structure
92
硼替佐米杂质92Bortezomib Impurity 92
Bortezomib Impurity 92
CAS No.444576-08-3
Chemical FormulaC25H35BN4O8
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 94 structure
94
硼替佐米杂质94Bortezomib Impurity 94
Bortezomib Impurity 94
CAS No.2308-61-4
Chemical FormulaC18H18N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Bortezomib Impurity 96 structure
96
硼替佐米杂质96Bortezomib Impurity 96
Bortezomib Impurity 96
CAS No.140614-17-1
Chemical FormulaC6H15BO2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

硼替佐米 —— 研究文献与合成路线Bortezomib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 硼替佐米 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Bortezomib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation
    Pino LK, Baeza J, Lauman R, et al. · Journal of proteome research · 2021 · 被引 63cited 63
  2. Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination
    Hoch L, Bourg N, Degrugillier F, et al. · Frontiers in pharmacology · 2022 · 被引 11cited 11
  3. Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation
    Wei M, Wang F, Huang D, et al. · Clinical and experimental medicine · 2026
  4. Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation
    Li C, Chen S, Yue P, et al. · The Journal of biological chemistry · 2020 · 被引 2cited 2
  5. Azidohomoalanine (AHA) Metabolic Labeling Reveals Unique Proteomic Insights into Protein Synthesis and Degradation in Response to Bortezomib Treatment
    Alhourani L, Tabana Y, Anand A, et al. · Proteomes · 2025
  6. Separation, identification and characterization of stress degradation products of bortezomib using HPLC and LC-MS
    Purushotham Reddy C, Ramakrishna K, Narayana Rao K · European journal of mass spectrometry (Chichester, England) · 2021

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF BORTEZOMIB
    KUMAR SATISH, DURVASULA VENUGOPAL VENKATARAMA, RATHOD PARENDU DHIRAJLAL, ARYAN RAM CHANDER · 公开号 WO2011098963WO2011098963 · 2011
  2. PROCESS FOR MAKING BORTEZOMIB AND INTERMEDIATES FOR THE PROCESS
    CASTULIK JAKUB, ZABADAL MIROSLAV · 公开号 WO2012048745WO2012048745 · 2012
  3. BORTEZOMIB AND PROCESS FOR PRODUCING SAME
    MURKI VEERENDER, PALLE RAGHAVENDRACHARYULU VENKATA, KADABOINA RAJASEKHAR, MANDA AMARENDHAR, et al. · 公开号 MX2010002836MX2010002836 · 2010
  4. POLYMORPHIC FORMS OF BORTEZOMIB AND PROCESS FOR THEIR PREPARATION
    RAVI JANAKI RAMA RAO, PULLA REDDY MUDDASANI, ADIBATLA KALI SATYA BHUJANGA RAO, BENKAIAH CHOWDARY NANNAPANENI · 公开号 WO2008075376WO2008075376 · 2008
  5. BORTEZOMIB AND PROCESS FOR PRODUCING SAME
    PALLE RAGHAVENDRACHARYULU VENKATA, KADABOINA RAJASEKHAR, MURKI VEERENDEER, MANDA AMARENDHAR, et al. · 公开号 US2010226597US2010226597 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

硼替佐米 杂质谱研究要点Bortezomib — impurity profiling notes

下面这些是拿到 硼替佐米 的 54 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 54 impurity entries for Bortezomib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances